Full Text View
Tabular View
No Study Results Posted
Related Studies
Ocular Surface Changes in Patients With Cystic Fibrosis
This study is currently recruiting participants.
Study NCT00345280   Information provided by University of Bialystok
First Received: June 27, 2006   Last Updated: June 16, 2008   History of Changes

June 27, 2006
June 16, 2008
August 2006
 
 
 
Complete list of historical versions of study NCT00345280 on ClinicalTrials.gov Archive Site
 
 
 
Ocular Surface Changes in Patients With Cystic Fibrosis
Chosen Parameters of the Immune Response in the Origin of Ocular Changes in Patients With Cystic Fibrosis

Cystic fibrosis(CF) is an inherited disease affecting children, adolescents and young adults with dysfunction of secretory glands.It is caused by mutations in the protein-coding gene which function as the cystic fibrosis transmembrane regulator (CFTR), responsible for the secretion of chloride ions in epithelial cells, adenocytes, sweat gland cells, pancreatic ducts,alimentary and respiratory tracts and eye. Assessment of the relationship between the inflammatory processes and apoptosis in the eye in the course of cystic fibrosis will allow determination of immunological exponents which may facilitate diagnosis.

The aim: To assess the role of chosen parameters of immunological response in the induction of ocular changes in cystic fibrosis patients, particularly chosen chemokine concentrations in the tear fluid and analysis of chosen apoptotic markers expression on conjunctival epithelial cells.

Phase I
Observational
Observational Model:  Cohort
Time Perspective:  Prospective
Eye Manifestations
Procedure: impression cytology, obtain the tear fluid
Vitamin A
Other Name: Becton Dickinson
 
 

*   Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
 
Recruiting
26
September 2008
 

Inclusion Criteria:

  • male and female patients aged 3-25 with clinically definite diagnosis of cystic fibrosis
  • all patients must give written consent for participation in the study at screening

Exclusion Criteria:

  • patients with a history of chronic disease of the immune system
  • patients with the history of systemic diseases
  • patients with the history chronic ocular diseases
  • patients who have been treated with corticosteroids in the past 3 months prior to the screening visit
Both
3 Years to 25 Years
Yes
Contact: Michal Sewerynski, Prof. +48 22 6281944 minister@mnisw.gov.pl
Poland
 
NCT00345280
Malgorzata Mrugacz, Medical University of Bialystok, Poland
8789, N40605131/1894
University of Bialystok
 
Principal Investigator: Malgorzata Mrugacz, MD, PhD Department of Pediatric Ophthalmology Medical University of Bialystok, Poland
University of Bialystok
June 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP